Skip to main content

SILVERARC CAPITAL MANAGEMENT, LLC

Position in CCCC — C4 Therapeutics, Inc.

CIK 1816307 BOSTON, MA

Position in CCCC

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$14,159,720
+$9,131,726 QoQ
Shares Held
3,032,060
+58.6% QoQ
Ownership
2.46%
of shares outstanding
% of Portfolio
1.58%
of 13F equity value
Holder Rank
#14
of 147 holders
Holding Since
Mar 2024
9 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in CCCC Over Time

Shares Held

Position Value (USD)

Derivatives in CCCC

reported options exposure · as of Sep 30, 2024
CallValue
$855,000
CallShares
150,000
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

SILVERARC CAPITAL MANAGEMENT, LLC holds $802,586,993 across 53 Biotechnology names. CCCC ranks #19 (1.8% of the industry book) .

# Ticker Company Shares Value (USD) Open

All Filings in CCCC

Export CSV
10 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $14,159,720 3,032,060
2026-03-31 $5,027,994 1,911,785
2025-12-31 $3,808,967 1,994,224
2025-09-30 $4,212,190 1,897,383
2025-03-31 $1,411,680 882,300
2024-12-31 $4,396,071 1,221,131
2024-09-30 $855,000 150,000
2024-09-30 $6,542,978 1,147,891
2024-06-30 $6,665,925 1,442,841
2024-03-31 $11,731,556 1,435,931